User menu

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.

Bibliographic reference Constantinescu, Stefan N. ; Leroy, Emilie ; Gryshkova, Vitalina ; Pecquet, Christian ; Dusa, Alexandra. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.. In: Biochemical Society Transactions, Vol. 41, no.4, p. 1048-1054 (2013)
Permanent URL
  1. Ziemiecki Andrew, Harpur Ailsa G., Wilks Andrew F., JAK protein tyrosine kinases: their role in cytokine signalling, 10.1016/0962-8924(94)90143-0
  2. Hilkens Catharien M.U., Is'harc Hayaatun, Lillemeier Björn F., Strobl Birgit, Bates Paul A., Behrmann Iris, Kerr Ian M., A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130, 10.1016/s0014-5793(01)02783-1
  3. Haan Claude, Is'harc Hayaatun, Hermanns Heike M., Schmitz-Van de Leur Hildegard, Kerr Ian M., Heinrich Peter C., Grötzinger Joachim, Behrmann Iris, Mapping of a Region within the N Terminus of Jak1 Involved in Cytokine Receptor Interaction, 10.1074/jbc.m106135200
  4. Huang Lily Jun-shen, Constantinescu Stefan N., Lodish Harvey F., The N-Terminal Domain of Janus Kinase 2 Is Required for Golgi Processing and Cell Surface Expression of Erythropoietin Receptor, 10.1016/s1097-2765(01)00401-4
  5. Radtke Simone, Hermanns Heike M., Haan Claude, Schmitz-Van de Leur Hildegard, Gascan Hugues, Heinrich Peter C., Behrmann Iris, Novel Role of Janus Kinase 1 in the Regulation of Oncostatin M Receptor Surface Expression, 10.1074/jbc.m100822200
  6. Ragimbeau J., The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression, 10.1093/emboj/cdg038
  7. Constantinescu S. N., Keren T., Socolovsky M., Nam H.-s., Henis Y. I., Lodish H. F., Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain, 10.1073/pnas.081069198
  8. Brown Richard J, Adams Julian J, Pelekanos Rebecca A, Wan Yu, McKinstry William J, Palethorpe Kathryn, Seeber Ruth M, Monks Thea A, Eidne Karin A, Parker Michael W, Waters Michael J, Model for growth hormone receptor activation based on subunit rotation within a receptor dimer, 10.1038/nsmb977
  9. Haan Claude, Kreis Stephanie, Margue Christiane, Behrmann Iris, Jaks and cytokine receptors—An intimate relationship, 10.1016/j.bcp.2006.04.013
  10. Seubert Nadine, Royer Yohan, Staerk Judith, Kubatzky Katharina F, Moucadel Virginie, Krishnakumar Shyam, Smith Steven O, Constantinescu Stefan N, Active and Inactive Orientations of the Transmembrane and Cytosolic Domains of the Erythropoietin Receptor Dimer, 10.1016/s1097-2765(03)00389-7
  11. Witthuhn Bruce A., Quelle Frederick W., Silvennoinen Olli, Yi Taolin, Tang Bo, Miura Osamu, Ihle James N., JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin, 10.1016/0092-8674(93)90414-l
  12. Darnell J., Kerr I., Stark G., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins, 10.1126/science.8197455
  13. Vainchenker William, Dusa Alexandra, Constantinescu Stefan N., JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies, 10.1016/j.semcdb.2008.07.002
  14. Shaw M. H., Boyartchuk V., Wong S., Karaghiosoff M., Ragimbeau J., Pellegrini S., Muller M., Dietrich W. F., Yap G. S., A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity, 10.1073/pnas.1930781100
  15. Li Z., Gakovic M., Ragimbeau J., Eloranta M.-L., Ronnblom L., Michel F., Pellegrini S., Two Rare Disease-Associated Tyk2 Variants Are Catalytically Impaired but Signaling Competent, 10.4049/jimmunol.1203118
  16. Russell S. M., Tayebi N., Nakajima H., Riedy M. C., Roberts J. L., Aman M. J., Migone T.-S., Noguchi M., Markert M. L., Buckley R. H., O'Shea J. J., Leonard W. J., Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development, 10.1126/science.270.5237.797
  17. Saharinen Pipsa, Silvennoinen Olli, The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction, 10.1074/jbc.m205156200
  18. Saharinen P., Takaluoma K., Silvennoinen O., Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain, 10.1128/mcb.20.10.3387-3395.2000
  19. Ungureanu Daniela, Wu Jinhua, Pekkala Tuija, Niranjan Yashavanthi, Young Clifford, Jensen Ole N, Xu Chong-Feng, Neubert Thomas A, Skoda Radek C, Hubbard Stevan R, Silvennoinen Olli, The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling, 10.1038/nsmb.2099
  20. Bandaranayake Rajintha M, Ungureanu Daniela, Shan Yibing, Shaw David E, Silvennoinen Olli, Hubbard Stevan R, Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F, 10.1038/nsmb.2348
  21. Ishida-Takahashi R., Rosario F., Gong Y., Kopp K., Stancheva Z., Chen X., Feener E. P., Myers M. G., Phosphorylation of Jak2 on Ser523 Inhibits Jak2-Dependent Leptin Receptor Signaling, 10.1128/mcb.01589-05
  22. Argetsinger L. S., Kouadio J.-L. K., Steen H., Stensballe A., Jensen O. N., Carter-Su C., Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity, 10.1128/mcb.24.11.4955-4967.2004
  23. Feng J, Mol. Cell. Biol., 17, 2497 (1997)
  24. Remy I., Wilson I. A., Michnick S. W., Erythropoietin Receptor Activation by a Ligand-Induced Conformation Change, 10.1126/science.283.5404.990
  25. James Chloé, Ugo Valérie, Le Couédic Jean-Pierre, Staerk Judith, Delhommeau François, Lacout Catherine, Garçon Loïc, Raslova Hana, Berger Roland, Bennaceur-Griscelli Annelise, Villeval Jean Luc, Constantinescu Stefan N., Casadevall Nicole, Vainchenker William, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, 10.1038/nature03546
  26. Baxter E, Lancet, 365, 1054 (2005)
  27. Levine Ross L., Wadleigh Martha, Cools Jan, Ebert Benjamin L., Wernig Gerlinde, Huntly Brian J.P., Boggon Titus J., Wlodarska Iwona, Clark Jennifer J., Moore Sandra, Adelsperger Jennifer, Koo Sumin, Lee Jeffrey C., Gabriel Stacey, Mercher Thomas, D’Andrea Alan, Fröhling Stefan, Döhner Konstanze, Marynen Peter, Vandenberghe Peter, Mesa Ruben A., Tefferi Ayalew, Griffin James D., Eck Michael J., Sellers William R., Meyerson Matthew, Golub Todd R., Lee Stephanie J., Gilliland D. Gary, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, 10.1016/j.ccr.2005.03.023
  28. Kralovics Robert, Passamonti Francesco, Buser Andreas S., Teo Soon-Siong, Tiedt Ralph, Passweg Jakob R., Tichelli Andre, Cazzola Mario, Skoda Radek C., A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders, 10.1056/nejmoa051113
  29. Lu Xiaohui, Huang Lily Jun-Shen, Lodish Harvey F., Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F, 10.1074/jbc.m707125200
  30. Wernig G., Gonneville J. R., Crowley B. J., Rodrigues M. S., Reddy M. M., Hudon H. E., Walz C., Reiter A., Podar K., Royer Y., Constantinescu S. N., Tomasson M. H., Griffin J. D., Gilliland D. G., Sattler M., The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes, 10.1182/blood-2007-07-102186
  31. Dusa Alexandra, Staerk Judith, Elliott Joanne, Pecquet Christian, Poirel Hélène A., Johnston James A., Constantinescu Stefan N., Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2, 10.1074/jbc.m709302200
  32. Ma Wanlong, Kantarjian Hagop, Zhang Xi, Yeh Chen-Hsiung, Zhang Zhong J., Verstovsek Srdan, Albitar Maher, Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias, 10.2353/jmoldx.2009.080114
  33. Mead Adam J., Rugless Michelle J., Jacobsen Sten Eirik W., Schuh Anna, GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis, 10.1056/nejmc1200349
  34. Mead A. J., Chowdhury O., Pecquet C., Dusa A., Woll P., Atkinson D., Burns A., Score J., Rugless M., Clifford R., Moule S., Bienz N., Vyas P., Cross N., Gale R. E., Henderson S., Constantinescu S. N., Schuh A., Jacobsen S. E. W., Impact of isolated germline JAK2V617I mutation on human hematopoiesis, 10.1182/blood-2012-05-430926
  35. Dusa Alexandra, Mouton Céline, Pecquet Christian, Herman Murielle, Constantinescu Stefan N., JAK2 V617F Constitutive Activation Requires JH2 Residue F595: A Pseudokinase Domain Target for Specific Inhibitors, 10.1371/journal.pone.0011157
  36. Gnanasambandan Kavitha, Magis Andrew, Sayeski Peter P., The Constitutive Activation of Jak2-V617F Is Mediated by a π Stacking Mechanism Involving Phenylalanines 595 and 617, 10.1021/bi1014858
  37. Lindauer Klaus, Loerting Thomas, Liedl Klaus R., Kroemer Romano T., Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation, 10.1093/protein/14.1.27
  38. Giordanetto Fabrizio, Kroemer Romano T., Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7, 10.1093/protein/15.9.727
  39. Mohammadi Moosa, Schlessinger Joseph, Hubbard Stevan R, Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism, 10.1016/s0092-8674(00)80131-2
  40. Lee Tai-Sung, Ma Wanlong, Zhang Xi, Giles Francis, Kantarjian Hagop, Albitar Maher, Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations, 10.1002/cncr.24183
  41. Wan Shunzhou, Coveney Peter V., Regulation of JAK2 Activation by Janus Homology 2: Evidence from Molecular Dynamics Simulations, 10.1021/ci300308g
  42. Wan Xiaobo, Ma Yue, McClendon Christopher L., Huang Lily Jun-shen, Huang Niu, Ab Initio Modeling and Experimental Assessment of Janus Kinase 2 (JAK2) Kinase-Pseudokinase Complex Structure, 10.1371/journal.pcbi.1003022
  43. Jura N., Shan Y., Cao X., Shaw D. E., Kuriyan J., Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3, 10.1073/pnas.0912101106
  44. Shan Y., Arkhipov A., Kim E. T., Pan A. C., Shaw D. E., Transitions to catalytically inactive conformations in EGFR kinase, 10.1073/pnas.1220843110
  45. Zhao Lequn, Dong Hongyun, Zhang Cheng Cheng, Kinch Lisa, Osawa Mitsujiro, Iacovino Michelina, Grishin Nikolai V., Kyba Michael, Huang Lily Jun-shen, A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation, 10.1074/jbc.m109.011387
  46. Gorantla S. P., Dechow T. N., Grundler R., Illert A. L., zum Buschenfelde C. M., Kremer M., Peschel C., Duyster J., Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice, 10.1182/blood-2009-07-236133
  47. Malka Yaniv, Hornakova Tekla, Royer Yohan, Knoops Laurent, Renauld Jean-Christophe, Constantinescu Stefan N., Henis Yoav I., Ligand-independent Homomeric and Heteromeric Complexes between Interleukin-2 or -9 Receptor Subunits and the γ Chain, 10.1074/jbc.m803125200
  48. Hornakova Tekla, Staerk Judith, Royer Yohan, Flex Elisabetta, Tartaglia Marco, Constantinescu Stefan N., Knoops Laurent, Renauld Jean-Christophe, Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers, 10.1074/jbc.m807531200
  49. Lupardus Patrick J., Skiniotis Georgios, Rice Amanda J., Thomas Christoph, Fischer Suzanne, Walz Thomas, Garcia K. Christopher, Structural Snapshots of Full-Length Jak1, a Transmembrane gp130/IL-6/IL-6Rα Cytokine Receptor Complex, and the Receptor-Jak1 Holocomplex, 10.1016/j.str.2010.10.010
  50. Kershaw Nadia J, Murphy James M, Liau Nicholas P D, Varghese Leila N, Laktyushin Artem, Whitlock Eden L, Lucet Isabelle S, Nicola Nicos A, Babon Jeffrey J, SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition, 10.1038/nsmb.2519
  51. Kornev A. P., Haste N. M., Taylor S. S., Ten Eyck L. F., Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism, 10.1073/pnas.0607656103
  52. Staerk Judith, Kallin Anders, Demoulin Jean-Baptiste, Vainchenker William, Constantinescu Stefan N., JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation : CROSS-TALK WITH IGF1 RECEPTOR, 10.1074/jbc.c500358200
  53. Flex Elisabetta, Petrangeli Valentina, Stella Lorenzo, Chiaretti Sabina, Hornakova Tekla, Knoops Laurent, Ariola Cristina, Fodale Valentina, Clappier Emmanuelle, Paoloni Francesca, Martinelli Simone, Fragale Alessandra, Sanchez Massimo, Tavolaro Simona, Messina Monica, Cazzaniga Giovanni, Camera Andrea, Pizzolo Giovanni, Tornesello Assunta, Vignetti Marco, Battistini Angela, Cavé Hélène, Gelb Bruce D., Renauld Jean-Christophe, Biondi Andrea, Constantinescu Stefan N., Foà Robin, Tartaglia Marco, Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia, 10.1084/jem.20072182
  54. Mullighan C. G., Zhang J., Harvey R. C., Collins-Underwood J. R., Schulman B. A., Phillips L. A., Tasian S. K., Loh M. L., Su X., Liu W., Devidas M., Atlas S. R., Chen I-M., Clifford R. J., Gerhard D. S., Carroll W. L., Reaman G. H., Smith M., Downing J. R., Hunger S. P., Willman C. L., JAK mutations in high-risk childhood acute lymphoblastic leukemia, 10.1073/pnas.0811761106
  55. Jeong E. G., Kim M. S., Nam H. K., Min C. K., Lee S., Chung Y. J., Yoo N. J., Lee S. H., Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers, 10.1158/1078-0432.ccr-07-4839
  56. Wartman Lukas D., Larson David E., Xiang Zhifu, Ding Li, Chen Ken, Lin Ling, Cahan Patrick, Klco Jeffery M., Welch John S., Li Cheng, Payton Jacqueline E., Uy Geoffrey L., Varghese Nobish, Ries Rhonda E., Hoock Mieke, Koboldt Daniel C., McLellan Michael D., Schmidt Heather, Fulton Robert S., Abbott Rachel M., Cook Lisa, McGrath Sean D., Fan Xian, Dukes Adam F., Vickery Tammi, Kalicki Joelle, Lamprecht Tamara L., Graubert Timothy A., Tomasson Michael H., Mardis Elaine R., Wilson Richard K., Ley Timothy J., Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression, 10.1172/jci45284
  57. Scott Linda M., Tong Wei, Levine Ross L., Scott Mike A., Beer Philip A., Stratton Michael R., Futreal P. Andrew, Erber Wendy N., McMullin Mary Frances, Harrison Claire N., Warren Alan J., Gilliland D. Gary, Lodish Harvey F., Green Anthony R., JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis, 10.1056/nejmoa065202
  58. Gnanasambandan Kavitha, Magis Andrew T., Sayeski Peter P., A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L, 10.1007/s11010-012-1326-7
  59. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., Macintyre E. A., Villeval J.-L., Vainchenker W., Berger R., Bernard O. A., Delabesse E., Penard-Lacronique V., Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia, 10.1182/blood-2006-09-045963
  60. Bercovich Dani, Ganmore Ithamar, Scott Linda M, Wainreb Gilad, Birger Yehudit, Elimelech Arava, Shochat Chen, Cazzaniga Giovanni, Biondi Andrea, Basso Giuseppe, Cario Gunnar, Schrappe Martin, Stanulla Martin, Strehl Sabine, Haas Oskar A, Mann Georg, Binder Vera, Borkhardt Arndt, Kempski Helena, Trka Jan, Bielorei Bella, Avigad Smadar, Stark Batia, Smith Owen, Dastugue Nicole, Bourquin Jean-Pierre, Tal Nir Ben, Green Anthony R, Izraeli Shai, Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome, 10.1016/s0140-6736(08)61341-0
  61. Weigert Oliver, Lane Andrew A., Bird Liat, Kopp Nadja, Chapuy Bjoern, van Bodegom Diederik, Toms Angela V., Marubayashi Sachie, Christie Amanda L., McKeown Michael, Paranal Ronald M., Bradner James E., Yoda Akinori, Gaul Christoph, Vangrevelinghe Eric, Romanet Vincent, Murakami Masato, Tiedt Ralph, Ebel Nicolas, Evrot Emeline, De Pover Alain, Régnier Catherine H., Erdmann Dirk, Hofmann Francesco, Eck Michael J., Sallan Stephen E., Levine Ross L., Kung Andrew L., Baffert Fabienne, Radimerski Thomas, Weinstock David M., Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition, 10.1084/jem.20111694
  62. Walters Denise K., Mercher Thomas, Gu Ting-Lei, O'Hare Thomas, Tyner Jeffrey W., Loriaux Marc, Goss Valerie L., Lee Kimberly A., Eide Christopher A., Wong Matthew J., Stoffregen Eric P., McGreevey Laura, Nardone Julie, Moore Sandra A., Crispino John, Boggon Titus J., Heinrich Michael C., Deininger Michael W., Polakiewicz Roberto D., Gilliland D. Gary, Druker Brian J., Activating alleles of JAK3 in acute megakaryoblastic leukemia, 10.1016/j.ccr.2006.06.002